REGEnBRAIN: a non-invasive medical device for the treatment of concussions
REGEnLIFE is preparing to commercialize REGEnBRAIN, intended, upon medical advice, to treat patients who have suffered a concussion within 72 hours.
REGEnLIFE is preparing to commercialize REGEnBRAIN, the 1st non-invasive brain stimulation medical device using light (red and near-infrared spectra) currently undergoing CE marking (according to Regulation (EU) 2017/745).
REGEnBRAIN treats acute concussion symptoms.
REGEnBRAIN is a medical neurostimulation technology designed for easy use by healthcare professionals or caregivers trained in its operation.
The performance and benefit results obtained have shown:
REGEnBRAIN is particularly suited for sports medicine (for sports with concussion risks such as boxing, rugby, handball, basketball, ice hockey, combat sports, judo, etc.), but also for military medicine or traumatology (falls, domestic accidents, road accidents, etc.).
REGEnBRAIN is a non-invasive medical device usable in healthcare facilities, medical practices, and outpatient care. The tri-photonic technique uses photobiomodulation (PBM) combined with a static magnetic field (SMF), precisely delivered by an ergonomically designed headset to targeted brain areas.
Thanks to a streamlined and user-friendly interface, treatment can be easily initiated with a single button press.
REGEnBRAIN Features:
Scientific Partnerships: Advancing Clinical Research Together
Are you a clinician, researcher, or scientific project leader interested in setting up clinical study protocols to evaluate the effectiveness of REGEnBRAIN in other pathological contexts?
REGEnLIFE’s mission is to bring together scientific expertise, technological innovation, and clinical needs to offer therapeutic solutions to patients and healthcare professionals.
Contact REGEnLIFE to discuss potential synergies between your expertise and our innovative technology.
